JNJ-67571244 mediates potent tumor activity in vivo in 2 established murine AML models. (A) T cell–engrafted NSG mice bearing established KG-1 tumors were intraperitoneally dosed with JNJ-67571244 at 0.1, 0.5, and 1 mg/kg (denoted by bar below x-axis). Tumor volume was measured twice weekly and the results presented as the mean tumor volume ± standard error of the mean for each group (statistical significance denoted by asterisk). (B) T cell–engrafted NSG mice bearing disseminated MOLM-13-luc cells were intraperitoneally dosed with JNJ-67571244 at 0.005, 0.05, and 0.5 mg/kg (denoted by bar below x-axis). Survival was determined by using Kaplan-Meier survival analysis (statistical significance denoted by asterisks). (C) Same as panel B but here bioluminescence was measured twice weekly, and representative images of live animal imaging of bioluminescence (ventral and dorsal views of n = 3-5 animals) on days 9, 13, and 16 are shown (n = 3 in control group on day 16 due to mortality). (D) Similar to panel B but here mice were dosed with JNJ-67571244 at 0.005 and 0.05 mg/kg for 3 doses. T-cell infiltration in the bone marrow was measured by flow cytometric analysis, and results are presented as percent tumor cells (top panel) or percent CD3⁺ T cells (bottom panel). (E) Same as panel D but here T-cell infiltration in bone marrow was measured by IHC staining, and results are presented as CD33⁺ tumor cells (top panel) or CD8⁺ T cells (bottom panel). Scale bar, 500 μm.